Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer

KARIN SÖDERLUND LEIFLER1, SIV QUESETH1, TOMMY FORNANDER2 and MARIE STENMARK ASKMALM1

1Linköping University, Department of Clinical and Experimental Medicine, Division of Surgery and Clinical Oncology, Linköping; 2Karolinska University Hospital, Department of Oncology, Stockholm, Sweden

Received May 25, 2010; Accepted July 9, 2010

DOI: 10.3892/ijo_00000808

Abstract. The purpose was to study the prognostic and predictive roles of DNA protein kinase catalytic subunit (DNA-PKcs), Ku70/80 and p53 for the effect of radiotherapy in breast cancer patients. Protein expressions of Ku70/80, DNA-PKcs and p53 were examined using immunohistochemistry in tumours from 224 breast cancer patients, who were randomised to receive post-operative radiotherapy or adjuvant chemotherapy (cyclophosphamide, methotrexate, 5-fluorouracil). One hundred and twenty-nine (60%) of the tumours had low expression of Ku70/80, 122 (57%) had low expression of DNA-PKcs and 65 (30%) had altered p53 expression. None of the proteins were indicative to the prognosis of local recurrence-free survival. Even though the expression of Ku70/80 and DNA-PKcs correlated well, they were not associated with treatment outcome in the same way. Low expression of Ku70/80 predicted good effect of radiotherapy (RR=0.31, 95% CI 0.13-0.76, p=0.01). In contrast, the greatest benefit of radiotherapy over chemotherapy was seen in patients with high DNA-PKcs expression (RR=0.25, 95% CI 0.07-0.84, p=0.02). Altered p53 expression predicted poor response to radiotherapy. We believe that the results reflect the different roles of DNA-PKcs and Ku70/80 in repair and cell death regulation after DNA damage. These differences could be of importance when developing drugs that target DNA repair.

Introduction

A majority of patients with locally advanced breast cancer are treated with adjuvant radiotherapy (RT) to reduce the risk of locoregional recurrence and possibly prolong breast cancer-specific survival (1). However, there is a need for markers that can predict which patients are likely to benefit from radiotherapy.

The efficiency of DNA damage repair is one of the most important determinants of radiation sensitivity (2). Other factors that influence radiosensitivity are hypoxia (3), cell cycle phase (4), and possibly also the ability of the tumour cells to undergo apoptosis (5,6). Several of these factors are linked to the molecular profile of tumour cells. Ionising radiation (IR) employed in radiotherapy induces different types of damage, of which the double-strand breaks show the best correlation with the level of cell killing (reviewed in ref. 7). Double-strand breaks are repaired by two distinct, but sometimes overlapping, mechanisms: non-homologous end-joining (NHEJ) and homologous recombination (HR). Homologous recombination is an essentially error-free process acting predominantly in the late S and G2 phases of the cell cycle, in which a homologous template is used to ensure correct restoration of the damaged DNA sequence (8). In contrast, NHEJ is a more approximate repair mechanism. During NHEJ the broken ends are resected or processed, with potential loss of nucleotides at the repair site, and the backbone is subsequently ligated.

One of the key players in NHEJ is DNA-dependent protein kinase (DNA-PK). It is a complex consisting of DNA-PK catalytic subunit (DNA-PKcs) and a regulatory heterodimer of Ku70 and Ku80 (or Ku86), which are constitutively expressed at relatively high levels in cells (9). The Ku heterodimer binds to DNA ends with high affinity independently of DNA sequence (10). Ku recruits DNA-PKcs to the DNA and the interaction between Ku and DNA-PKcs stimulates the catalytic potential of the DNA-PK complex (11). To date, >20 proteins have been reported to be substrates of DNA-PK, including AKT/PKB, Artemis, XRCC4 and p53 (12,13).

The DNA-PKcs gene is defect in mice with severe combined immunodeficiency syndrome (SCID) (14). The scid mutation confers immunodeficiency and radiation hypersensitivity due to deficiencies in the processing of DSB intermediates during development of the immune system and DNA repair. Similarly, mice with mutated Ku70 also display defect DNA repair and hypersensitivity to ionising radiation (15). Furthermore, experimental studies have shown that inhibition of DNA-PK cause radiosensitisation in vitro and in vivo (16-19). This is in line with the central role of the DNA-PK complex in DNA repair, and forms the basis of...
methotrexate 40 mg/m² i.v. on days 1 and 8, 5-fluorouracil
ipsilateral internal mammary nodes. Chemotherapy was given
rapy. Individually dose-planned postoperative radiotherapy
attempts were fixed in formalin and embedded in paraffin.
node metastases or a tumour diameter exceeding 30 mm. After
being surgically removed by modified radical mastectomy,
tumours were fixed in formalin and embedded in paraffin.
with regard to tumour and treatment characteristics (data not
In 1988, the protocol was
changed to six courses of CMF instead of 12. The median
follow-up time was 13.1 years. Fifty-one patients experienced
histologically verified local recurrence and 114 had distant
recurrence. Patients have given their informed consent regard-
ning participation in the randomised study. The use of human
tissue for retrospective analysis of prognostic and predictive
factors was approved by the local ethics committee.

**DNA-PKcs and Ku70/80 immunohistochemical staining.**
Tissue microarray blocks with triplicate samples from each
tumour were constructed using a Tissue Microarrayer (Beecher
Instruments, Sun Prairie, WI, USA) as previously described
(26). DNA-PKcs antigen retrieval was performed by heating
in citrate buffer (pH 6.0) in an incubator at 78°C for 24 h.
Antigen retrieval was not necessary for the Ku70/80 epitope.
Endogenous peroxidase activity was blocked by 3% hydrogen
peroxide (H₂O₂)/methanol. Primary mouse monoclonal anti-
odies (Neomarkers, Fremont, CA) against DNA-PKcs (Ab-3,
cloned 42-psc, directed against amino acids 2713-3198 of the
4128 residues in the protein) and Ku (p70/p80) (Ab-3, clone
162, that recognises a conformational epitope of the hetero-
dimer) were used at a concentration of 2 μg/ml. Antibody
incubations were performed at room temperature; the DNA-
PKcs antibody for 2 h and the Ku70/80 antibody for 30 min.

After washing, slides were incubated with Dako
EnVision+ Mouse (Dako, Carpinteria, CA) for 30 min at
room temperature. Positively stained cells were visualised
with 3'-diaminobenzidine tetrahydrochloride (DAB) solution,
counterstained with haematoxylin and the slides were mounted.
As negative controls mouse IgG1 or IgG2a isotype-matched
irrelevant antibodies (Sigma, St. Louis, MO) were used at the
same dilutions as the corresponding primary antibodies.
Slides with tonsil tissue were used as positive controls for
staining (Neomarkers). Slides with normal, unmatched breast
tissue were stained together with the tissue microarray slides.

Staining, which was nuclear for both DNA-PKcs and
Ku70/80, was evaluated visually and independently by two
investigators. Tumours were grouped according to the per-
centage of tumour cells with positive staining: negative, 1-25,
26-50, 51-75 and 76-100%. In addition, staining intensity was
graded as negative, low, moderate or strong. In the statistical
analyses, expression of DNA-PKcs and Ku70/80 were divided
into low (0-75% positive tumour cells) or high (76-100%
positive tumour cells). A cut-off level around 75% positive
cells has been used in several previous studies (27-31).

**Material and methods**

**Patients and tumours.** In 1976, a prospective clinical trial
that compared postoperative radiotherapy with adjuvant
chemotherapy was initiated by the Stockholm Breast Cancer
Study Group (25). The current study is performed on tumour
material from a subset of 224 premenopausal women included
in that trial. The subset of patients in the present study did
not differ significantly from all the patients in the main study
with regard to tumour and treatment characteristics (data not
shown). Inclusion criteria were histologically verified lymph
node metastases or a tumour diameter exceeding 30 mm. After
being surgically removed by modified radical mastectomy,
tumours were fixed in formalin and embedded in paraffin.
Patients were randomised to receive radiotherapy or chemother-
apy. Individually dose-planned postoperative radiotherapy
was given with a high-voltage technique at a total dose of
46 Gy, with 2 Gy per fraction 5 days a week. The target volume
included the chest wall, axilla, Supraclavicular fossa and the
ipsilateral internal mammary nodes. Chemotherapy was given
according to the first Milan trial protocol, with 12 courses of
CMF (cyclophosphamide 100 mg/m² orally on days 1-14,
methotrexate 40 mg/m² i.v. on days 1 and 8, 5-fluorouracil
600 mg/m² i.v. on days 1 and 8). In 1988, the protocol was

Nuclear p53 staining in tumour cells was visually evaluated
by two independent investigators. Staining intensity was
graded as negative, weak or strong, and the percentage of
stained cells was categorised into six groups: negative, <10,
10-25, 26-50, 51-75 and 76-100%. Tumours that had strong

**p53 immunohistochemical staining.** Slides were pretreated
with 1 mM EDTA/Tris buffer (pH 9.0) and heated for 40 min
in high temperature waterbath (96-98°C). Staining of p53
was performed using a TechMate500 Instrument (Dako)
according to protocol by the manufacturer, using a mouse
monoclonal p53 antibody (clone DO-7, Dako) at dilution
1:100 and Dako EnVision Detection Kit, peroxidase/DAB,
rabbit/mouse (Dako). Slides were counterstained with haema-
toxyl, dehydrated in graded ethanol and mounted.

Nuclear p53 staining in tumour cells was visually evaluated
by two independent investigators. Staining intensity was
graded as negative, weak or strong, and the percentage of
stained cells was categorised into six groups: negative, <10,
10-25, 26-50, 51-75 and 76-100%. Tumours that had strong
staining in >10% of the cells were considered to have altered p53.

Statistical analysis. Relationships between variables were assessed by the χ²-test. Estimation of the probabilities of recurrence-free survival was performed with the Kaplan-Meier product limit method. Relative rate (RR) and p-values of recurrence were estimated using Cox's proportional hazard regression. Univariate analysis of local recurrence-free survival in relation to protein expression was analysed in the CMF-treated patient group only (prognosis). Variables included in multivariate analyses were histologic grade as estimated by the Nottingham grading system (NHG 1-3), tumour size (≤20 mm or >20 mm), number of positive lymph nodes, oestrogen receptor (ER) expression (cut-off value 0.1 fmol/μg DNA) and treatment modality (CMF/radiotherapy). Interaction tests were performed as a Cox analysis, which included the covariates x, treatment and the interaction term x* treatment. p-values of ≤0.05 were considered statistically significant. All statistical analyses were made using Statistica software version 7.1 (Statsoft, Tulsa, OK, USA). Of the 224 tumours, 8 were missing from the Ku70/80 staining, 9 from DNA-PKcs staining and 9 from p53 staining.

Results

Expression of Ku70/80 and DNA-PKcs in normal breast and breast tumours. Normal breast epithelium showed strong staining intensity for both Ku70/80 and DNA-PKcs in 26-50% of epithelial cells (Fig. 1). When divided according to percentage of positive cells with a cut-off at 75%, 129 (60%) tumours were categorised as having low expression of Ku70/80 and 122 (57%) had low expression of DNA-PKcs (Table I). The expression of DNA-PKcs and the Ku70/80 heterodimer were strongly correlated (p<0.001). Sixty-five (30%) of the tumours had altered p53 expression.

Prediction of treatment outcome. Radiotherapy significantly decreased the risk of local recurrence as compared to chemotherapy (p=0.04), as previously reported for this material (26). The greatest benefit of radiotherapy was seen in patients whose tumours had low expression of Ku70/80 (RR=0.31,
95% CI 0.13-0.76, p=0.01), whereas there was no benefit from radiotherapy over chemotherapy in patients with high expression (RR=0.80, 95% CI 0.31-2.02, p=0.63) (Fig. 2). In contrast, patients whose tumours had low expression of DNA-PKcs had no significant benefit of radiotherapy (RR=0.65, 95% CI 0.31-1.40, p=0.27), but in patients with high DNA-PKcs expression the risk of local recurrence was significantly lower with radiotherapy as compared to chemotherapy (RR=0.25, 95% CI 0.07-0.84, p=0.02) (Fig. 3). The interaction variables Ku70/80*RT and DNA-PKcs*RT were not statistically significant in interaction tests (p=0.15 and p=0.18, respectively). Similar results were obtained if the expression was evaluated in terms of staining intensity; in other words, negative-weak staining of Ku70/80 but moderate-strong staining of DNA-PKcs was related to benefit of radiotherapy (data not shown).

In terms of p53 status, there was a significant difference in the effect of radiotherapy on local tumour control as compared with chemotherapy in patients whose tumours had normal expression of p53 (RR=0.42, 95% CI 0.19-0.90, p=0.03) (Fig. 4). This benefit of radiotherapy was not seen in patients with altered p53 (RR=1.04, 95% CI 0.39-2.79, p=0.94). The interaction between p53 status and RT was not statistically significant (p=0.15).

We also examined the relation between DNA-PKcs expression and p53 status on the response to radiotherapy. In the subgroup of patients with normal p53 in their tumours, there was a borderline significant benefit of radiotherapy if the tumour at

<table>
<thead>
<tr>
<th>Table I. Distribution of staining intensity and fraction of positively stained cells of DNA-PKcs, Ku70/80 and p53 in breast tumours.</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNA-PKcs</td>
</tr>
<tr>
<td>Intensity</td>
</tr>
<tr>
<td>Negative</td>
</tr>
<tr>
<td>Weak</td>
</tr>
<tr>
<td>Moderate</td>
</tr>
<tr>
<td>Strong</td>
</tr>
<tr>
<td>Missing</td>
</tr>
<tr>
<td>% positive nuclei</td>
</tr>
<tr>
<td>1-25</td>
</tr>
<tr>
<td>26-50</td>
</tr>
<tr>
<td>51-75</td>
</tr>
<tr>
<td>76-100</td>
</tr>
<tr>
<td>Missing</td>
</tr>
</tbody>
</table>

*aStaining pattern in normal breast (not available for p53). Values in parentheses represent percentage.
the same time showed high expression of DNA-PKcs (RR=0.22, 95% CI 0.05-1.02, p=0.05) (Fig. 5a). The effect of radiotherapy on tumours with normal p53 was not significant in tumours with low DNA-PKcs expression (RR=0.47, 95% CI 0.18-1.26, p=0.13) (Fig. 5c), nor in tumours with altered p53 (high DNA-PKcs: RR=0.41, 95% CI 0.05-3.54, p=0.42; low DNA-PKcs: RR=1.37, 95% CI 0.37-5.15, p=0.64) (Fig. 5b and d). The subgroup with normal p53 benefitted significantly from radiotherapy if the tumour also expressed low levels of Ku70/80 (RR=0.28, 95% CI 0.09-0.83, p=0.02), but not if Ku70/80 expression was high (RR=0.53, 95% CI 0.16-1.83, p=0.32).

Correlation to prognostic markers and prognosis. High expression of Ku70/80 was correlated to ER positivity (p=0.02). High expression of DNA-PKcs correlated with high histologic grade and large tumour size (p=0.02 and p=0.05). Altered p53 correlated to high histologic grade (p<0.001) and oestrogen receptor negativity (p=0.002).

In univariate analysis, expression of Ku70/80 was not related to the prognosis of local recurrence-free survival of the patients (RR=0.66, 95% CI 0.32-1.38, p=0.27), neither was the expression of DNA-PKcs (RR=1.16, 95% CI 0.59-2.28, p=0.66). Similarly, there was no significant relation between altered expression of p53 and probability of local recurrence (RR=0.90, 95% CI 0.42-1.95, p=0.80). Treatment modality and positive lymph nodes were prognostic factors associated with risk of local recurrence in both univariate and multivariate analysis, whereas for distant recurrence tumour size and lymph node status were prognostic factors (Table II).

Discussion

In this study, low protein expression of the Ku70/80 heterodimer predicted good response to radiotherapy in early breast cancer. Even though the expression of Ku70/80 and DNA-PKcs were highly correlated, the different components in the DNA-PK complex did not influence treatment outcome in the same way. Somewhat surprisingly, it was high expression of DNA-PKcs, and not low expression, that was related to a significant benefit of radiotherapy in this material.

The difference that we observed between Ku70/80 and DNA-PKcs might be a result by chance; however, it is possible...
that this difference can be explained by their individual characteristics and functions. DNA-PKcs appears to be restricted to higher eukaryotes, while Ku70 and Ku80 exist in organisms ranging from yeast to man (10). The function of Ligase IV is completely dependent on Ku but not on DNA-PKcs, illustrating that the components of the DNA-PK complex have different functions (32). DNA-PKcs, by virtue of its kinase activity, belongs to a family of phosphatidylinositol 3-kinase-like protein kinases. It has the ability to phosphorylate itself \textit{in vivo} on residue Thr2609 in response to DNA damage, and mutation of this residue leads to radiosensitivity and impaired rejoining of double-strand breaks (33).

In addition to its involvement in NHEJ repair, the kinase activity of DNA-PK also seems to be important in the signaling of DNA damage. The cellular response to DNA damage

![Figure 5](0.png)

Figure 5. Probability of local recurrence-free survival in relation to the combined expression of DNA-PKcs and p53. Estimates of relative risk refer to RT as compared to CT. The variables were coded 0 (CT) and 1 (RT) and risks were estimated by Cox's proportional hazards model. Numbers represent events (local recurrences) per total number of patients in each group. RT, radiotherapy; CT, chemotherapy (cyclophosphamide, methotrexate and 5-fluouracil).

Table II. Multivariate analysis of local and distant relapse including prognostic factors and treatment modality.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Local recurrence</th>
<th>Distant recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RR (95% CI)</td>
<td>p-value</td>
</tr>
<tr>
<td>Treatment</td>
<td>0.41 (0.20-0.84)</td>
<td>0.015</td>
</tr>
<tr>
<td>Tumour grade</td>
<td>1.53 (0.90-2.61)</td>
<td>0.12</td>
</tr>
<tr>
<td>Positive lymph nodes</td>
<td>1.92 (1.13-3.27)</td>
<td>0.0017</td>
</tr>
<tr>
<td>Tumour size</td>
<td>1.22 (0.62-2.40)</td>
<td>0.56</td>
</tr>
<tr>
<td>ER status</td>
<td>0.74 (0.37-1.46)</td>
<td>0.38</td>
</tr>
<tr>
<td>DNA-PKcs</td>
<td>0.92 (0.47-1.81)</td>
<td>0.81</td>
</tr>
<tr>
<td>Ku70/80</td>
<td>0.76 (0.38-1.50)</td>
<td>0.42</td>
</tr>
</tbody>
</table>
includes DNA repair, induction of apoptosis and cell cycle arrest. The tumour suppressor p53 is a key molecule in the coordination of these functions after genotoxic treatment. p53 is activated by several different kinases, including DNA-PK (22). Although DNA-PK does not seem to be involved in communication with the cell cycle checkpoint machinery through p53, it appears that it has an important role in apoptotic signalling (34). Radiation-induced apoptosis in mouse thymocytes, which is mediated by p53, is suppressed in DNA-PKcs-/- mice (35). In contrast, cell cycle arrest and p21-induction is normal in these cells. Similarly, IR-induced apoptosis in adenovirus E1A-sensitised mouse embryonic fibroblasts is abolished in the absence of DNA-PKcs (36). Taken together, these results indicate that phosphorylation of p53 by DNA-PK might selectively activate apoptotic pathways and that the kinase activity of DNA-PKcs is important in this aspect. Thus, it seems that in addition to its role in DNA repair, the DNA-PK complex can contribute to apoptosis as a response to ionising radiation, at least in cells with functioning p53. In this study, patients whose tumours had normal p53 benefitted from radiotherapy as compared to chemotherapy. Patients with altered p53 did not respond well to radiotherapy. When patients were divided into four subgroups according to the combined expression of p53 and DNA-PKcs, the benefit from radiotherapy was most evident in the subgroup of patients whose tumours had normal p53 combined with high expression of DNA-PKcs. The relative risk of recurrence (for patients treated with radiotherapy, as compared to chemotherapy-treated patients) in the subgroups was gradually increased if p53 was altered or DNA-PKcs expression low, and the highest when both these criteria were met. The number of patients in the different subgroups was however small, and the results should be interpreted with caution. This observation is in line with the findings discussed above that p53-mediated apoptosis induced by radiation is suppressed in cells with reduced DNA-PKcs levels. Similar results were obtained in a study on tonsillar carcinoma by Friesland et al, who found that among patients with p53 wild-type tumours, those who also had high levels of DNA-PKcs had longer survival times after radiotherapy than patients with low DNA-PKcs expression (28).

There are a handful of studies on the relationships between DNA-PKcs, Ku70, Ku80 and radiosensitivity in other tumour types, which have yielded different and sometimes contradicting results. Our results are supported by two different studies on cervical carcinoma, in which tumour response to radiotherapy and overall patient survival were better if the expression of Ku70 or Ku80 was low (27,37). Similarly, there seems to be a correlation between low Ku70 expression and good histopathological response, as well as longer patient survival, after pre-operative radiotherapy in rectal cancer (30,38). A recent study suggests that the DNA-PK complex is upregulated in cervical carcinoma cells surviving radiotherapy, indicating that upregulation of DNA-PK may be involved in radioresistance (39). Two studies have found no significant correlation between expression of the DNA-PK subunits and radiosensitivity (31,40). In the current study, we found that high, rather than low expression, of DNA-PKcs was related to a good response to radiotherapy. This finding is in part similar to a study on squamous tonsillar carcinoma by Friesland et al, in which tumours with high expression of DNA-PKcs or Ku86 were more sensitive to radiotherapy (28).

These discrepancies between studies might in part be attributable to differences in tumour origin. Differences in the estimation of tumour radiosensitivity (e.g. in vitro measurements, tumour response in vivo, tumour control and patient survival) probably also contribute to disparities in the results and conclusions, and it is possible that the choice of antibodies also can affect the result. The antibodies used in this study have been employed in several other studies (28,40,41). The expression of Ku70 and Ku80 are highly correlated when detected with immunohistochemistry and it has been shown that the stabilities of the two heterodimer components are dependent on each other in vitro (27,42).

During the last decades the treatment of patients who have undergone breast cancer surgery has evolved greatly. Patients in the present study received CMF or radiotherapy, treatments that cannot be compared in terms of efficacy to the therapy offered today to breast cancer patients with the same clinical spread of the disease. The present study is randomised, which facilitates analysis of prognosis and prediction of treatment outcome as compared to the more complex, multimodality breast cancer treatment available today.

For the same study cohort, we have recently reported that low expression of the BRCA1/BRCA2/RAD51 complex in HR repair is associated with increased risk of local recurrence in early breast cancer (43). However, patients whose tumours had reduced levels of these proteins did also benefit from radiotherapy as compared to chemotherapy, suggesting that loss of this repair complex impairs the ability of the tumour cells to repair the radiation-induced damage correctly. In opposition to these findings, we have previously shown that high expression of the BRCA1/BRCA2/RAD51 complex in tumour cells is related to good response to radiotherapy (26). Our finding that high expression of DNA-PKcs predicts good effect of radiotherapy is similar to this result, and if these results hold true in subsequent studies they could be an example of the intricate balance between repair, cell cycle arrest and cell death after radiation damage. Recently, a role for NBS1 in apoptosis induction following DNA damage was reported, and it was suggested that NBS1 promotes apoptosis by regulating the inhibitory Bax-Ku70 interaction (44). A dual role for these proteins in both DNA repair as well as cell death regulation might explain why high expression seems to be related to better response to radiotherapy.

The results from this study indicate that low expression of the Ku heterodimer, but high expression of DNA-PKcs, predict good effect of radiotherapy, and probably reflect the complexity of the networks that regulate the fate of a cell after exposure to ionising radiation. It would be important to keep this complexity in mind when developing individualised cancer treatments that target proteins in the DNA damage signalling and repair pathways.

Acknowledgements

We thank Najme Wall and Jan Olofsson for classifying the tumours according to the Nottingham grading system,
Lambert Skoog for sharing his great knowledge on breast tumour pathology. This work was supported by grants from the Swedish Cancer Society.

References


